Literature DB >> 17005711

Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation.

George I Varughese1, Jeetesh V Patel, Joseph Tomson, Gregory Y H Lip.   

Abstract

BACKGROUND: Increased levels of plasma von Willebrand factor (vWf, an index of endothelial damage/dysfunction) and soluble P-selectin (sP-sel, an index of platelet activation) concentrations have been reported as indices of the prothrombotic state in both non-valvular atrial fibrillation and hypertension separately. However, the effect of hypertension on the levels of these indices in the setting of atrial fibrillation, and whether increasing severity of hypertension presents an additive prothrombotic risk, is unclear.
METHODS: Plasma concentrations of vWf and sP-sel were measured by ELISA in 1235 patients with atrial fibrillation, and levels related to a history of hypertension and rising quartiles of systolic, diastolic and pulse pressure in those with and without diabetes mellitus and prior vascular events.
RESULTS: Mean plasma vWf was higher among patients with atrial fibrillation with a history of hypertension (149 vs 145 IU/dl, p = 0.005). Also, an increase in the levels of vWf with increasing quartiles of pulse pressure (p = 0.042) was noticed. However, on multivariate analysis, after adjusting for potential confounders, the effects of both hypertension and pulse pressure became non-significant (p = 0.261 and p = 0.5, respectively). Levels of sP-sel were unaffected by a history of hypertension and rising quartiles of systolic and diastolic blood pressure, or pulse pressure.
CONCLUSION: Among patients with atrial fibrillation, patients with hypertension have higher vWf levels, indicating endothelial damage/dysfunction, which is associated with increasing pulse pressure. However, these associations are probably owing to the presence of other associated cardiovascular disease, rather than hypertension itself. Furthermore, platelet activation (sP-sel) was unrelated to hypertension or blood pressure in this atrial fibrillation cohort. Hypertension or blood pressure levels do not seem to have an independent additive affect on the prothrombotic state in atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005711      PMCID: PMC1861468          DOI: 10.1136/hrt.2006.099374

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  31 in total

Review 1.  Atrial fibrillation and stroke : concepts and controversies.

Authors:  R G Hart; J L Halperin
Journal:  Stroke       Date:  2001-03       Impact factor: 7.914

Review 2.  Is hypertension an inflammatory process?

Authors:  Christopher J Boos; Gregory Y H Lip
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

3.  Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage.

Authors:  M Fukuchi; J Watanabe; K Kumagai; Y Katori; S Baba; K Fukuda; T Yagi; A Iguchi; H Yokoyama; M Miura; Y Kagaya; S Sato; K Tabayashi; K Shirato
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

4.  Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study.

Authors:  I Goldsmith; P Kumar; P Carter; A D Blann; R L Patel; G Y Lip
Journal:  Am Heart J       Date:  2000-11       Impact factor: 4.749

5.  Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation.

Authors:  Sridhar Kamath; Andrew D Blann; Graham J Caine; David Gurney; Bernard S P Chin; Gregory Y H Lip
Journal:  Stroke       Date:  2002-05       Impact factor: 7.914

6.  Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors.

Authors:  Dwayne S G Conway; Lesly A Pearce; Bernard S P Chin; Robert G Hart; Gregory Y H Lip
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

7.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

Authors:  S Connolly; J Pogue; R Hart; M Pfeffer; S Hohnloser; S Chrolavicius; M Pfeffer; S Hohnloser; S Yusuf
Journal:  Lancet       Date:  2006-06-10       Impact factor: 79.321

8.  Effect of degree of blood pressure on the hypercoagulable state in chronic atrial fibrillation.

Authors:  F L Li-Saw-Hee; A D Blann; G Y Lip
Journal:  Am J Cardiol       Date:  2000-10-01       Impact factor: 2.778

9.  Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

Authors:  Charles G C Spencer; David Gurney; Andrew D Blann; D Gareth Beevers; Gregory Y H Lip
Journal:  Hypertension       Date:  2002-07       Impact factor: 10.190

10.  Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals.

Authors:  A D Blann; C N McCollum; G Y Lip
Journal:  Blood Coagul Fibrinolysis       Date:  2002-09       Impact factor: 1.276

View more
  2 in total

Review 1.  Global Changes in Food Supply and the Obesity Epidemic.

Authors:  Emilie H Zobel; Tine W Hansen; Peter Rossing; Bernt Johan von Scholten
Journal:  Curr Obes Rep       Date:  2016-12

Review 2.  Von Willebrand Factor Plasma Levels Variability In Nonvalvular Atrial Fibrillation.

Authors:  Gerardo Muñoz Cortés; Martha Eva Viveros Sandoval; Carlos Arturo Areán Martínez; Helios Eduardo Vega Gómez; Sandra Edith López Castañeda; Anel Gómez García
Journal:  J Atr Fibrillation       Date:  2014-12-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.